HLB shares plummet following FDA rejection of liver cancer drug approval

Korea Biomedical Review

17 May 2024 - HLB revealed that its US subsidiary, Elevar Therapeutics, and their Chinese partner, Jiangsu Hengrui Pharmaceuticals, received a complete response letter from the US FDA regarding its hepatocellular carcinoma combination treatment candidate of rivoceranib and camrelizumab.

The complete response letter highlighted two main issues.

Read Korea Biomedical Review article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine